Medicine information CIAMBRA 500mg powder for concentrate for solution for infusion

Product code:
W63201001
Quantity:
1
Indicated for:
non-small cell lung cancer
Route of administration:
infusion
Substance:
pemetrexeda (antimetabolite antineoplastic)
ATC
L01BA04 — Antineoplastic and immunomodulating agents | Antimetabolites | Folic acid analogues
Pemetrexed is a chemotherapy agent used in the treatment of lung cancer and malignant pleural mesothelioma. It works by inhibiting enzymes involved in DNA and RNA synthesis, thereby preventing tumor cell growth.

The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to follow the treatment regimen and take folic acid and vitamin B12 supplements to reduce the risk of side effects.

Patients should be aware of potential side effects, such as fatigue, nausea, or decreased blood cell counts. It is important to inform the doctor of any unusual symptoms.

Common side effects include fatigue, nausea, and anemia. In rare cases, severe reactions such as hematologic toxicity or allergic reactions may occur. Patients should be informed of these risks before use.

General data about CIAMBRA 500mg

Substance:
pemetrexeda
Date of latest medicines list:
01-03-2017
Product code:
W63201001
Strength:
500mg
Pharmaceutical form:
powder for concentrate for solution for infusion
Quantity:
1
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
ONCOTEC PHARMA PRODUKTION GMBH - GERMANIA
Holder:
MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. - LUXEMBURG
Number:
1055/2015/02
Shelf life:
3 years

Strengths available for pemetrexeda

  • 1000mg
  • 100mg
  • 10mg/ml
  • 25mg/ml
  • 500mg

Official documents

The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.

Added to database:
03/05/2016
Source record updated:
17/10/2024

Warnings:

Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling

Handle with special care.

Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity

This medicine may affect the liver.

Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.